Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
11.33
-0.26 (-2.24%)
At close: Apr 28, 2026, 4:00 PM EDT
11.34
+0.01 (0.09%)
After-hours: Apr 28, 2026, 7:13 PM EDT
Phathom Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Phathom Pharmaceuticals stock have an average target of 19.83, with a low estimate of 5.00 and a high estimate of 28. The average target predicts an increase of 75.02% from the current stock price of 11.33.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 27, 2026.
Analyst Ratings
The average analyst rating for Phathom Pharmaceuticals stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 1 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Hold → Buy Upgrades $16 → $18 | Hold → Buy | Upgrades | $16 → $18 | +58.87% | Mar 27, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $20 → $25 | Strong Buy | Maintains | $20 → $25 | +120.65% | Feb 27, 2026 |
| Barclays | Barclays | Hold Initiates $16 | Hold | Initiates | $16 | +41.22% | Dec 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $26 | Strong Buy | Maintains | $20 → $26 | +129.48% | Oct 31, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $12 → $17 | Strong Buy | Maintains | $12 → $17 | +50.04% | Jun 9, 2025 |
Financial Forecast
Revenue This Year
338.04M
from 175.11M
Increased by 93.04%
Revenue Next Year
537.19M
from 338.04M
Increased by 58.91%
EPS This Year
-0.59
from -3.03
EPS Next Year
1.16
from -0.59
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 351.8M | 599.8M | ||||||
| Avg | 338.0M | 537.2M | ||||||
| Low | 319.0M | 479.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 100.9% | 77.4% | ||||||
| Avg | 93.0% | 58.9% | ||||||
| Low | 82.2% | 41.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 1.83 | ||||||
| Avg | -0.59 | 1.16 | ||||||
| Low | -1.13 | 0.62 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.